FDA plans ultra-fast review of three psychedelic drugs following Trump directive
The Food and Drug Administration says it will offer ultra-fast review to three psychedelic drugs being studied for hard-to-treat mental health conditions, including depression.
Original Source
Read the full article at Seattletimes →KhanList aggregates and links to publicly available news content. We do not host full articles from third-party sources. Always verify important information with original sources.